PL2327763T3 - Generowanie komórek T specyficznych względem antygenu - Google Patents

Generowanie komórek T specyficznych względem antygenu

Info

Publication number
PL2327763T3
PL2327763T3 PL10179257T PL10179257T PL2327763T3 PL 2327763 T3 PL2327763 T3 PL 2327763T3 PL 10179257 T PL10179257 T PL 10179257T PL 10179257 T PL10179257 T PL 10179257T PL 2327763 T3 PL2327763 T3 PL 2327763T3
Authority
PL
Poland
Prior art keywords
cells
specific
antigen
generation
directed
Prior art date
Application number
PL10179257T
Other languages
English (en)
Inventor
Dolores Schendel
Susanne Wilde
Thomas Blankenstein
Original Assignee
Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt Gmbh
Max-Delbrück-Centrum Für Molekulare Medizin (Mdc)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt Gmbh, Max-Delbrück-Centrum Für Molekulare Medizin (Mdc) filed Critical Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt Gmbh
Publication of PL2327763T3 publication Critical patent/PL2327763T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4245—Tyrosinase or tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
PL10179257T 2005-08-05 2006-08-04 Generowanie komórek T specyficznych względem antygenu PL2327763T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP05017128 2005-08-05
EP06007539 2006-04-10
EP06776623A EP1910521B1 (en) 2005-08-05 2006-08-04 Generation of allorestricted antigen specific t cells
EP10179257.0A EP2327763B1 (en) 2005-08-05 2006-08-04 Generation of antigen specific T cells

Publications (1)

Publication Number Publication Date
PL2327763T3 true PL2327763T3 (pl) 2018-08-31

Family

ID=37598202

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10179257T PL2327763T3 (pl) 2005-08-05 2006-08-04 Generowanie komórek T specyficznych względem antygenu

Country Status (11)

Country Link
US (2) US8486694B2 (pl)
EP (3) EP2327763B1 (pl)
JP (3) JP5079697B2 (pl)
AT (1) ATE484578T1 (pl)
DE (1) DE602006017556D1 (pl)
DK (2) DK1910521T3 (pl)
ES (2) ES2672895T3 (pl)
HU (1) HUE038833T2 (pl)
PL (1) PL2327763T3 (pl)
PT (1) PT2327763T (pl)
WO (1) WO2007017201A1 (pl)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10112851C1 (de) * 2001-03-16 2002-10-10 Gsf Forschungszentrum Umwelt Semi-allogene Antitumor-Vakzine mit HLA-haplo-identischen Antigen-präsentierenden Zellen
US7994298B2 (en) 2004-09-24 2011-08-09 Trustees Of Dartmouth College Chimeric NK receptor and methods for treating cancer
WO2007017201A1 (en) * 2005-08-05 2007-02-15 Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt Gmbh Generation of antigen specific t cells
EP2098536A1 (en) 2008-03-05 2009-09-09 4-Antibody AG Isolation and identification of antigen- or ligand-specific binding proteins
CN102272153B (zh) 2008-11-24 2015-04-15 德国慕尼黑亥姆霍兹研究中心健康和环境有限公司 高亲和力t细胞受体及其应用
WO2010089412A1 (en) * 2009-02-09 2010-08-12 Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Fuer Gesundheit Und Umwelt (Gmbh) Repertoire of allo-restricted peptide-specific t cell receptor sequences and use thereof
US12492376B2 (en) 2009-10-29 2025-12-09 The Trustees Of Dartmouth College T-cell receptor-deficient T cell compositions
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
ES2635335T3 (es) * 2010-09-20 2017-10-03 Biontech Cell & Gene Therapies Gmbh Receptores de células T específicos de antígeno y epítopos de células T
US9833476B2 (en) 2011-08-31 2017-12-05 The Trustees Of Dartmouth College NKP30 receptor targeted therapeutics
ES2834070T3 (es) 2011-09-15 2021-06-16 Us Health Receptores de células T que reconocen MAGE restringido por HLA-A1 o HLA-Cw7
ES2719495T5 (en) 2012-05-07 2025-09-10 Dartmouth College Anti-b7-h6 antibody, fusion proteins, and methods of using the same
CN104411819B (zh) * 2012-06-11 2019-05-10 威尔逊沃夫制造公司 用于过继细胞疗法的改进的细胞培养方法
EP3718556A3 (en) 2012-08-31 2020-12-30 University Of Virginia Patent Foundation Target peptides for immunotherapy and diagnostics
EP4088737A3 (en) 2012-09-05 2023-02-08 University Of Virginia Patent Foundation Target peptides for colorectal cancer therapy and diagnostics
GB2508414A (en) * 2012-11-30 2014-06-04 Max Delbrueck Centrum Tumour specific T cell receptors (TCRs)
US10357515B2 (en) 2013-11-22 2019-07-23 Cellectis Method for generating batches of allogeneic T-cells with averaged potency
JP2017511375A (ja) 2014-03-20 2017-04-20 エイチ リー モフィット キャンサー センター アンド リサーチ インスティテュート インコーポレイテッド 養子細胞療法のための腫瘍浸潤リンパ球
CA2945816A1 (en) 2014-04-15 2015-10-22 University Of Virginia Patent Foundation Isolated t cell receptors and methods of use therefor
AU2014407539B2 (en) * 2014-10-02 2020-10-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating T cell receptors having antigenic specificity for a cancer-specific mutation
US10973894B2 (en) 2014-10-02 2021-04-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Methods of isolating T cells having antigenic specificity for a cancer-specific mutation
EP3215164A1 (en) 2014-11-03 2017-09-13 Immures S.r.l. T cell receptors
AU2015343013B2 (en) * 2014-11-05 2020-07-16 Board Of Regents, The University Of Texas System Gene modified immune effector cells and engineered cells for expansion of immune effector cells
MX384919B (es) * 2014-11-26 2025-03-14 Us Health Receptores de células t de kras anti-mutado.
SG11201707540QA (en) 2015-03-16 2017-10-30 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft Method of detecting new immunogenic t cell epitopes and isolating new antigen-specific t cell receptors by means of an mhc cell library
HK1253694A1 (zh) 2015-06-01 2019-06-28 Medigene Immunotherapies Gmbh T细胞受体文库
WO2016193300A1 (en) 2015-06-01 2016-12-08 Medigene Immunotherapies Gmbh Method for generating antibodies against t cell receptor
GB2592821B (en) 2015-07-31 2022-01-12 Univ Minnesota Modified cells and methods of therapy
JP7185524B2 (ja) * 2015-09-15 2022-12-07 アメリカ合衆国 Ｈｌａ－ｃｗ８拘束性の変異ｋｒａｓを認識するｔ細胞受容体
GB201520550D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
HUE053674T2 (hu) 2015-12-23 2021-07-28 Medigene Immunotherapies Gmbh Antigén-specifikus TCR receptorok új generációja
EP3397263B1 (en) * 2015-12-30 2023-09-20 Celgene Corporation T lymphocyte production methods and t lymphocytes produced thereby
MA45491A (fr) * 2016-06-27 2019-05-01 Juno Therapeutics Inc Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
CA3035075A1 (en) * 2016-09-23 2018-03-29 Fred Hutchinson Cancer Research Center Tcrs specific for minor histocompatibility (h) antigen ha-1 and uses thereof
JP7181862B2 (ja) 2016-10-18 2022-12-01 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 腫瘍浸潤リンパ球および治療の方法
WO2019006418A2 (en) 2017-06-30 2019-01-03 Intima Bioscience, Inc. ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
US20210061914A1 (en) * 2017-12-28 2021-03-04 Gritstone Oncology, Inc. Antigen-Binding Proteins Targeting Shared Antigens
JP7181517B2 (ja) * 2018-01-23 2022-12-01 国立大学法人三重大学 Ｔ細胞レセプター
CN111819194B (zh) 2018-02-26 2024-06-04 基因医疗免疫疗法有限责任公司 Nyeso t细胞受体(tcr)
MX2021001938A (es) * 2018-08-22 2021-04-19 Fred Hutchinson Cancer Center Inmunoterapia dirigida a antigenos kras o her2.
EP3849569A4 (en) * 2018-09-10 2022-06-08 Torque Therapeutics, Inc. ANTIGEN-SPECIFIC T LYMPHOCYTES AND METHODS OF MAKING AND USING THEM
AU2019351273A1 (en) * 2018-09-27 2021-05-20 Genocea Biosciences, Inc. Treatment methods
EP3894544A4 (en) * 2018-12-12 2023-03-29 The Brigham & Women's Hospital, Inc. Compositions and methods for immunosuppression
TWI850360B (zh) 2019-04-04 2024-08-01 德商梅迪基因免疫治療公司 黑色素瘤相關抗原１（ｍａｇｅａ１）特異性ｔ細胞受體及其用途
JP6878544B2 (ja) * 2019-10-02 2021-05-26 アメリカ合衆国 がん特異的突然変異に対し抗原特異性を有するｔ細胞を単離する方法
JP7340144B2 (ja) * 2019-10-02 2023-09-07 アメリカ合衆国 がん特異的突然変異に対し抗原特異性を有するｔ細胞を単離する方法
US20230080742A1 (en) * 2020-02-12 2023-03-16 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Hla class i-restricted t cell receptors against ras with g12d mutation
WO2021198163A1 (en) 2020-04-01 2021-10-07 Medigene Immunotherapies Gmbh Cd3-fusion protein and uses thereof
JP2020143057A (ja) * 2020-04-01 2020-09-10 アメリカ合衆国 がん特異的突然変異に対し抗原特異性を有するｔ細胞受容体を単離する方法
EP4146794A1 (en) * 2020-05-04 2023-03-15 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
US12173318B2 (en) 2020-08-18 2024-12-24 Medigene Immunotherapies Gmbh Enrichment of T cells using an anti-Cß antibody
WO2022063966A1 (en) 2020-09-24 2022-03-31 Medigene Immunotherapies Gmbh Prame specific t-cell receptors and uses thereof
AU2021388167A1 (en) * 2020-11-25 2023-07-06 Geneius Biotechnology, Inc. Antigen specific t cells and methods of making and using same
MX2023007003A (es) * 2020-12-14 2023-08-18 Biontech Us Inc Antigenos especificos de tejidos para la inmunoterapia del cancer.
WO2023175069A1 (en) 2022-03-16 2023-09-21 Medigene Immunotherapies Gmbh Tcr constant region pairing library for pramevld tcrs
EP4493583A1 (en) 2022-03-16 2025-01-22 Medigene Immunotherapies GmbH Tcr constant region pairing library
GB2640828A (en) * 2024-04-22 2025-11-12 T Therapeutics Ltd Methods and products for the generation and identification of T cells and TCRs

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2203782T3 (es) * 1996-01-17 2004-04-16 Imperial College Innovations Limited Inmunoterapia que utiliza linfocitos t citotoxicos (ctl).
ES2267937T3 (es) * 2002-08-23 2007-03-16 Deutsches Rheuma-Forschungszentrum Berlin Procedimiento de deteccion y aislamiento de linfocitos t que reconocen un antigeno definido.
WO2007017201A1 (en) * 2005-08-05 2007-02-15 Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt Gmbh Generation of antigen specific t cells

Also Published As

Publication number Publication date
ES2672895T3 (es) 2018-06-18
US8486694B2 (en) 2013-07-16
EP1910521A1 (en) 2008-04-16
EP3369812A1 (en) 2018-09-05
ES2842878T3 (es) 2021-07-15
JP2016135127A (ja) 2016-07-28
EP3369812B1 (en) 2020-10-07
PT2327763T (pt) 2018-05-11
US20100189728A1 (en) 2010-07-29
EP1910521B1 (en) 2010-10-13
EP2327763A1 (en) 2011-06-01
ATE484578T1 (de) 2010-10-15
US20140141026A1 (en) 2014-05-22
JP2009502185A (ja) 2009-01-29
DK2327763T3 (en) 2018-05-22
EP2327763B1 (en) 2018-03-14
JP5079697B2 (ja) 2012-11-21
DE602006017556D1 (de) 2010-11-25
DK1910521T3 (da) 2011-02-07
WO2007017201A1 (en) 2007-02-15
HUE038833T2 (hu) 2018-11-28
JP2012213402A (ja) 2012-11-08

Similar Documents

Publication Publication Date Title
PL2327763T3 (pl) Generowanie komórek T specyficznych względem antygenu
Tian et al. Cytotoxic CD4 T cells: differentiation, function, and application to dengue virus infection
Schatton et al. ABCB5 identifies immunoregulatory dermal cells
Wu et al. Thymic damage, impaired negative selection, and development of chronic graft-versus-host disease caused by donor CD4+ and CD8+ T cells
Roncarolo et al. Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans
Galli et al. Invariant NKT cells sustain specific B cell responses and memory
CY1121857T1 (el) Ενωσεις οι οποιες επεκτεινουν αιμοποιητικα βλαστοκυτταρα
Huntington et al. IL-15 transpresentation promotes both human T-cell reconstitution and T-cell–dependent antibody responses in vivo
RU2017111300A (ru) Центральные т-клетки памяти для адоптивной т-клеточной терапии
CY1114755T1 (el) Ρυθμιση των τ κυτταρων
Yamaki et al. OX40 and IL‐7 play synergistic roles in the homeostatic proliferation of effector memory CD4+ T cells
ATE506962T1 (de) Von survivin abgeleitete peptide und deren verwendung
CY1110557T1 (el) Αντισωματα ιντερλευκινης-10
WO2005000348A3 (en) Vaccines inducing nkt-cell and toll-like-receptor activation
WO2005004592A3 (en) Transgenic mice having a human major histocompatibility complex (mhc) phenotype, experimental uses and applications
BR0207399A (pt) Método de terapia com células para o tratamento de tumores
Lindqvist et al. T regulatory cells in B‐cell malignancy–tumour support or kiss of death?
Moon et al. Use of epigenetic modification to induce FOXP3 expression in naïve T cells
DK0952772T3 (da) Fremgangsmåder til anvendelse af mononukleare phagocytter til at fremme axonal regeneration
Wang et al. Repeated long‐term DT application in the DEREG mouse induces a neutralizing anti‐DT antibody response
JP2016513963A5 (pl)
DK1788078T3 (da) Dendritisk celle-lægemiddel indeholdende den dendritiske celle, terapeutisk fremgangsmåde under anvendelse af den dendritiske celle og fremgangsmåde til dyrkning af gammadelta-T-celle
PL378195A1 (pl) Inhibitory prezentacji antygenów przez cząsteczki MHC klasy II i sposoby ich zastosowania
Sun et al. Foxp3 regulates human natural CD4+ CD25+ regulatory T‐cell‐mediated suppression of xenogeneic response
BRPI0407002A (pt) Células cultivadas que apresentam antìgeno cd14+